Daraxonrasib, a targeted RAS inhibitor, demonstrated safety and efficacy in a Phase I/II trial for previously treated RAS-mutant metastatic pancreatic cancer.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
RAS(ON) inhibitor daraxonrasib shows promising results in advanced pancreatic cancer
Phase I/II First-In-Human Trial type
RAS-Mutant Metastatic Pancreatic Cancer Cancer type
Dana-Farber Cancer Institute Lead institution